SOURCE: PLATINE Pharma Services

PLATINE Pharma Services

June 24, 2013 12:20 ET

Platine Pharma and Indicia Biotechnology Join Forces to Strengthen Leadership in Immuno-Assays

LYON, FRANCE--(Marketwired - Jun 24, 2013) -

  • Platine Pharma Services acquires the Assay Development activities of Indicia Biotechnology
  • With this transaction, Platine gets access to Indicia's Immunoline™ proprietary platform and strengthens its position as a leader in immunomonitoring
  • Indicia Biotechnology becomes one of the major shareholders of Platine Pharma Services

Platine Pharma Services ("Platine"), a specialist in immunomonitoring services, and Indicia Biotechnology ("Indicia"), a company specialized in the development of bioassays, announce the signature of an agreement by which Platine will acquire the immuno-assays activities of Indicia.

With this acquisition, Platine Pharma Services enriches its service range solution to the biopharmaceutical, diagnostic and cosmetic industries. It notably gets access to Indicia's Immunoline™ proprietary platform for immunogenicity risk assessment of biologics and its immuno-assay development expertise. This operation consolidates Platine's unique services offer from assay development to the realization of complex clinical trials studies complying with high regulatory requirements, and will benefit Platine and Indicia's customer portfolio.

All activities will be operated within Platine's laboratories in the Center of Excellence for Infectious diseases of Lyon.

"By adding their complementary expertise and offers, Platine Pharma Services and Indicia Biotechnology join forces to build a leading platform able to deliver fit for purpose services from the R&D grade development of immunoassays to the highest quality level required for clinical studies," said Frederic Hammel, CEO of Platine Pharma Services, and Stéphane Legastelois, CEO of Indicia Biotechnology. They added: "This further strengthens Platine Pharma Services as a leader in immunomonitoring."

The transaction is a contribution in kind from Indicia Biotechnology of its immune-assay business to Platine who will issue new shares to compensate Indicia Biotechnology for its contribution. Indicia Biotechnology will own around 32% of Platine. The ownership of current shareholders of Platine (Innate Pharma and Transgene) will be reduced down to around 32% each.

The agreement was signed on June 19, 2013, and will be subject to shareholders approval of both companies in General Meeting to take place on July 31, 2013.

About Platine Pharma Services

Founded in 2011 and based in Lyon within the Infectious Disease Center, Platine Pharma Services is an essential source of immune information for scientists and clinicians. From protocol support to regulatory reports, the company designs, performs and interprets complex molecular and cellular assays highlighting key immune markers in both normal and pathological conditions. This information guides healthcare professionals in their decisions at each step of the development of prophylactic or therapeutic drugs against cancers, infectious and inflammatory diseases.

For more information: www.platine-lab.com

About Indicia Biotechnology

For over 15 years, the immune-technology specialist Indicia Biotechnology has been supporting bio-industries in their R&D projects, and providing services relating to immunoassays and in vitro testing.

The company is currently focusing its strategy on protein biomarkers of clinical interest and their applications for in vitro diagnostic.

By combining three competencies -- sample bio-analysis, assay development and IVD test production -- into a single offer, Indicia Biotechnology is intent on contributing to the boost in clinical programs.

For more information: www.indicia.fr

Press release: http://hugin.info/157221/R/1711642/567904.pdf

Contact Information